BioSpace News Archive

Turnstone Biologics Corp., a clinical-stage biotechnology company focused on the development of cancer immunotherapies, today announced the promotions of José Manuel Otero, Ph.D., to Chief Technology Officer, and Saryah Azmat to Chief Business Officer. Turnstone also announced that Mike Burgess, MB. ChB., Ph.D., will transition from President of R&D to Executive Chairman of R&D and be appointed to the Turnstone Board of Directors

Today, Vori Health, a first-class medical provider for innovative musculoskeletal care through technology, community and care teams, announced their Series A funding of $45MM

Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical development candidate, INZ-701, as a potential treatment for ABCC6 Deficiency.

- - - - The article states Pure-Vu System is estimated to provide lifetime saving of $833- $992 per patient when compared to standard of care for outpatient colorectal cancer (CRC) screening and surveillance colonoscopy - - - - The researchers indicated that approximately 25% of 15 million outpatient colonoscopies performed annually in the US, or 3.75 million are inadequately prepped

MedPod’s MobileDoc® device leverages latest advancements in live, two-way telediagnostic communications [07-May-2021] NEW YORK , May 7, 2021 /PRNewswire/ -- Ambulnz , Inc., d/b/a DocGo , a leading provider of last-mile telehealth and integrated medical mobility services that has entered into an agreement to merge with Motion Acquisition Corp. (Nasdaq: MOTN), today a

Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initial Phase 1 clinical pharmacokinetic (PK), safety, and preliminary efficacy data to be presented at American Society of Clinical Oncology (ASCO) Annual Meeting

Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research

TACTI-003 clinical trial design enables evaluation of efti in 1st line recurrent or metastatic HNSCC patients to better understand its effect in combination with pembrolizumab

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE)

Ensysce Biosciences, Inc. (“Ensysce”), which has entered into an agreement for a business combination with Leisure Acquisition Corp. (“LACQ”) (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that Ensysce’s subsidiary, Covistat, will be presenting at the upcoming American Thoracic Society (ATS) Annual Meeting